Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Study Start Date

2005-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lambert Eaton Myasthenic Syndrome (LEMS) is rare neurological disorder that results in muscle weakness and limited reflex activity. More than half of LEMS cases are associated with a malignancy, usually small cell lung cancer, and tend to progress more quickly than cases not coupled with malignant cells.

3,4diaminopyridine (3,4DAP)is a drug that has been demonstrated to be effective in treating the weakness associated with LEMS as it increases strength and improves autonomic symptoms in LEMS patients. It is not currently approved by the FDA for use in the United States. The investigators plan to use 3,4DAP to treat patients with LEMS here at the Columbia University MDA/ALS Research Center.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

NCT02090725

Muscle Weakness

TERMINATED PHASE2

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

NCT00704925

Lambert Eaton Myasthenic Syndrome

NO_LONGER_AVAILABLE

Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome

NCT01373333

Lambert-Eaton Myasthenic Syndrome

NO_LONGER_AVAILABLE

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

NCT02012933

Lambert-Eaton Myasthenic Syndrome (LEMS) Congenital Myasthenia (CM)

NO_LONGER_AVAILABLE

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

NCT01511978

Lambert-Eaton Myasthenic Syndrome Eaton-Lambert Myasthenic Syndrome

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lambert Eaton Myasthenic Syndrome (LEMS)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

3,4-diaminopyridine

Treatment will begin with 5mg three times a day or less.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be diagnosed with LEMS or a type of CMS likely to respond to 3, 4-DAP.
* If female of childbearing age, have negative pregnancy test, and be willing to practice and effective form of birth control during the study.
* Tested and found by ECG not to have a prolonged QTc syndrome.
* Agrees to have a second ECG at the time of peak drug effect. Has understood and signed the Informed Consent.

Exclusion Criteria

* Is known to have a sensitivity to 3, 4-DAP.
* Has a history of past or current seizures or of severe asthma, or has an epileptiform EEG.
* Is believed by the investigator to be unable to comply with the protocol.
* Is unable to give informed consent.
* No patient will be excluded based on race, ethnicity, gender, or HIV status

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No